我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
2
2 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
进行中（未招募）
100.0%
暂无批准数据
• TheraVectys has initiated a Phase I/IIa clinical trial for Lenti-HPV-07, an onco-therapeutic vaccine targeting cancers induced by human papillomavirus (HPV). • The trial will evaluate the safety, immunogenicity, and preliminary efficacy of Lenti-HPV-07 in 72 patients with oropharyngeal or cervical cancers across U.S. cancer centers. • Lenti-HPV-07, a lentiviral vector-based vaccine, has demonstrated complete tumor elimination and long-lasting immune memory in preclinical studies. • The trial includes patients with recurrent/metastatic cancers and newly diagnosed cases, assessing the vaccine's impact alone and in combination with anti-PD1 therapies.
